[Genetic polymorphisms as new predictive factors for successful treatment of chronic hepatitis C].

Authors:
Address: Clinic of infectology and travel medicine, University Hospital L. Pasteur's, Košice, Slovak Republic. ivalkova@yahoo.com
Journal:

Publication:

abstract

Currently, the gold standard for the treatment of chronic hepatitis C is combination therapy with pegylated interferon alpha and ribavirin. Despite advances in treatment modalities, only 50 % of patients achieve sustained virological response. Therefore, determination of predictive factors related to response to therapy is very important. In 2009, three independent studies concerning genome-wide association identified several single nucleotide polymorphisms near the IL-28 gene, associated with virological response. Hence, it appears that Genetic polymorphism may become important predictive factors. All patients beginning therapy, will probably be tested for the presence of these polymorphisms, allowing individualized treatment options for every patient.

Related Articles
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Hepatology. 2009
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, et al. Hepatology. 2009 Jun; 49(6):1847-58.
Review Interferon-lambda and therapy for chronic hepatitis C virus infection.
Trends Immunol. 2011
Review Interferon-lambda and therapy for chronic hepatitis C virus infection.
Donnelly RP, Dickensheets H, O'Brien TR. Trends Immunol. 2011 Sep; 32(9):443-50. Epub 2011 Aug 5.
Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.
Hepatogastroenterology. 2011
Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C.
Coban S, Idilman R, Erden E, Tüzün A. Hepatogastroenterology. 2011 Jul-Aug; 58(109):1301-6.
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
J Hepatol. 2011
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Lange CM, Moradpour D, Doehring A, Lehr HA, Müllhaupt B, Bibert S, Bochud PY, Antonino AT, Pascual M, Farnik H, et al. J Hepatol. 2011 Aug; 55(2):322-7. Epub 2010 Dec 13.
Review [Genome-wide association study on and the clinical application to chronic hepatitis C].
Uirusu. 2011
Review [Genome-wide association study on and the clinical application to chronic hepatitis C].
Sugiyama M, Mizokami M. Uirusu. 2011 Jun; 61(1):15-24.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.